SQZ SQZ Biotechnologies Company

Biotech Analyst Ratings

Latest News

1. 18 May 2022 SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

   Average Processing Time Per Batch Less Than 6 Hours – a 55% Reduction with Comparable or Improved Product Metrics

   First Clinical Use Planned for SQZ^® TACs in Celiac Disease with IND Submission Anticipated in 1H 2023

   Preclinical Data on Hematopoietic Stem Cell Engineering and Planned Commercial Research-Use-Only System Presented at ASGCT 2022 Support Potential for Broad Future Point-of-Care Manufacturing Implementation

   R&D Investor Event Featuring Point-of-Care Manufacturing Platform and Research-Use-Only System, Tomorrow, May 19, 2022

   SQZ Biotechnologies (NYSE:SQZ) announced today that the company's first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable…

   View Full Article
2. 10 May 2022 SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates

   •  Granted FDA Fast Track Designation for Lead APC Clinical Candidate
   • Received FDA IND Clearance to Initiate Phase 1/2 Clinical Trial of Next Generation eAPC Therapeutic Candidate for HPV16+ Solid Tumors
   • Published Peer Reviewed, Comprehensive Preclinical Research Supporting SQZ^® APC and TAC Therapeutic Programs
   • Anticipated SQZ^® APC, eAPC, and AAC Clinical Data for HPV16+ Solid Tumors in Second Half 2022

   SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported first quarter 2022 financial results and recent portfolio updates.

   "Our year is off to an exciting start with the FDA IND clearance to initiate clinical trials of our eAPCs – our multifunctional mRNA-based…

   View Full Article
3. 05 May 2022 SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022

   SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the company will host a live R&D investor event with optional virtual participation on Thursday, May 19, 2022, from 4:05 - 5:30 p.m. ET.

   The event will feature presentations on the company's point-of-care (POC) manufacturing system, currently in internal testing, and its potential impact on cell therapy development. The company will also discuss its first anticipated clinical use in the SQZ^® TAC clinical development program for celiac disease, which has an FDA investigational new drug application submission planned for the first half of 2023.

   Company leadership will also discuss the collaboration with…

   View Full Article
4. 05 May 2022 SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research

   SQZ's Point-of-Care (POC) Manufacturing Platform Shows Promising Results with Ability to Produce Cell Therapies at Scale in Under 10 Hours

   Co-Development of Research-Use-Only System with STEMCELL Technologies to Help Drive Cell Therapy Innovation by the Broader Scientific Community

   Presentations on the POC Manufacturing Platform, Research Scale System and Hematopoietic Stem Cell Engineering Preclinical Data at 2022 American Society for Gene and Cell Therapy Annual Meeting

   SQZ Biotechnologies (NYSE:SQZ) announced today that the company will present data from the first non-clinical studies of its point-of-care (POC) manufacturing system at the 2022 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting on May 18. The data will demonstrate…

   View Full Article
5. 03 May 2022 SQZ Biotechnologies to Present at Upcoming Investor Conferences

   SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, in Las Vegas, Nevada and at the H.C. Wainwright Global Investment Conference on May 25, in Miami, Florida. Presentation times and webcast information are available below.

   PRESENTATION DETAILS

   Tuesday, May 10
   Bank of America Securities 2022 Healthcare Conference
   5:00-5:30 p.m. ET / 2:00-2:30 p.m. PT
   Webcast

   Wednesday, May 25
   H.C. Wainwright Global Investment Conference
   9:30-10:00 a.m. ET
   Webcast

   Conference webcast details and the company's…

   View Full Article